Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila, Thomas A
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. [electronic resource] - Clinical lymphoma, myeloma & leukemia 03 2018 - 204-209 p. digital
Publication Type: Journal Article
2152-2669
10.1016/j.clml.2018.01.007 doi
Blood Cell Count--methods
Female
Humans
Induction Chemotherapy--methods
Leukemia, Myeloid, Acute--drug therapy
Male
Prognosis
Retrospective Studies
Time Factors
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. [electronic resource] - Clinical lymphoma, myeloma & leukemia 03 2018 - 204-209 p. digital
Publication Type: Journal Article
2152-2669
10.1016/j.clml.2018.01.007 doi
Blood Cell Count--methods
Female
Humans
Induction Chemotherapy--methods
Leukemia, Myeloid, Acute--drug therapy
Male
Prognosis
Retrospective Studies
Time Factors